1. Single dosing comparison of the relative cardiac, B,/ R activity of inhaled fenoterol and salbutamol in normal subjects;Newnham, D.M.; Wheeldon, N.M.; Lipworth, B.J.; McDevitt, D.G.;Thorax,1993
2. The pulmonary and extrapulmonary effects of inhaled Ol-agonists in patients with asthma;Wmdom, H.H.; Burgess, C.D.; Siebers, R.W.L.; Purdie, G.; Pearce, N.; Crane, J.;Clin Pharnacol Ther,1990
3. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline;Crane, J.; Burgess, C.; Beasley, R.;Thorax,1986
4. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers;Scheinin, M.; Koulu, M.; Laurikainen, E.; Allonen, H.;BrJ Clin Pharmacol,1987
5. Risks versus benefits of inhaled P2-agonists in the management of asthma;Lipworth, B.J.;Drug Safety,1992